Frontline therapy for newly diagnosed patients with multiple myeloma
- Author:
Sung-Hoon JUNG
1
;
Jae-Cheol JO
;
Ga-Young SONG
;
Seo-Yeon AHN
;
Deok-Hwan YANG
;
Jae-Sook AHN
;
Hyeoung-Joon KIM
;
Je-Jung LEE
Author Information
- Publication Type:REVIEW ARTICLE
- From:Blood Research 2020;55(S1):S37-S42
- CountryRepublic of Korea
- Language:0
- Abstract: Since the introduction of an alkylator to the treatment of multiple myeloma (MM), new effective agents have been developed, such as immunomodulatory drugs including thalidomide, lenalidomide, and pomalidomide; proteasome inhibitors including bortezomib, carfilzomib, and ixazomib; monoclonal antibodies including daratumumab and elotuzumab; and deacetylase inhibitors including panobinostat. Numerous regimens with these new agents have been developed and they have contributed in improving survival outcomes in MM patients. In addition, the recommended therapies for newly diagnosed MM change every year based on the results of clinical trials. This review will discusses the appropriate induction therapies based on recent clinical trials for patients with newly diagnosed MM.
